TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Probiotics in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the NICU~* Written parental consent~* Birth weight \< 2000 grams~* Hemodynamically stable~* \< 48 hours of age~Exclusion Criteria:~* Evidence or suspicion of congenital intestinal obstruction or perforation~* Prenatal or postnatal diagnosis of gastroschisis, large omphalocele, or congenital diaphragmatic hernia~* Major congenital heart defects~* Anticipated transfer to a NICU not involved in the study

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 48 Hours
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): 5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
- 2 (Type: EXPERIMENTAL): 5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For all patients~* history of clinically significant chronic cough for \> 3 months~* For COPD patients~* \>40 years of age~* 20-pack-year history of smoking~* GOLD classification of Stage 1 or higher~* For IPF patients~* \> 50 years of age~* history of unexplained dyspnea on exertion of \> 3 months~* exhibits coughing and bilateral, basilar, inspiratory crackles on physical exam~* presents as being in a stable phase of IPF~* lung biopsy or HRCT indicative of IPF~Exclusion Criteria:~* ACE inhibitor use~* GERD~* current cancer or history of lung cancer~* non-ambulatory~* hospitalized in the previous 12 months for heart failure

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): lozenges containing 150 IU of natural human interferon-alpha
- 2 (Type: PLACEBO_COMPARATOR): matching placebo lozenges

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post Abortion IUD & Recurrent Abortion 2001-2004

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female resident of Interior Health region seeking an abortion between January 1, 2001 and December 31, 2004~Exclusion Criteria:~* Women undergoing abortions for fetal genetic abnormalities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IUD (Type: None): Repeat abortion rate in women receiving IUDs immediately post-abortion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-ST-segment elevation acute myocardial infarction.~* coronary angiography within 48 hours from admission.~* angiographic evidence of severe and diffuse coronary artery disease,not amenable to conventional direct revascularisation techniques by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).~Exclusion Criteria:~* ST-segment elevation acute myocardial infarction,~* clinical history of heart failure~* left ventricular ejection fraction \<35%,~* any form of severe valvular dysfunction,~* previous implantation or indication to implant a cardioverter-defibrillator during the index admission,~* any increase in liver enzymes,~* history of any liver or muscle disease,~* renal failure with serum creatinine \>2.5 mg/dL (221 mmol/L),~* need for continued use of intravenous medications to relieve anginal symptoms,~* presence of any major comorbidity with life expectancy \<24 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full-dose atorovastatin (80 mg/d) (Type: EXPERIMENTAL): For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
- Conventional medical treatment (Type: NO_INTERVENTION): For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels \<100 mg/dL (2.5 mmol/L).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 16 years~* Biopsy-proven diagnosis of classical Hodgkin Lymphoma (regardless of HRS cell CD20 expression) per the World Health Organization classification criteria24; lymphocyte predominant histology is excluded~* Untreated relapse of classical Hodgkin Lymphoma (with the exception of steroids) as follows:HL that relapsed \> 3 months after completion of first-line chemotherapy or combined modality therapy, and has not yet been treated with salvage chemotherapy, Stage I-II HL that relapsed \> 3 months after first-line chemotherapy, then relapsed after radiation therapy delivered with curative intent, and has not yet been treated with salvage chemotherapy~* Radiographically measurable disease (\> 1 focus of lymphoma measuring \> 1.5 cm)~* Baseline laboratories: ANC \> 1000/uL and platelets \> 75,000/uL, unless due to bone marrow involvement by lymphoma, Serum creatinine \< 2.0 mg/dL, Total bilirubin \< 2.0 mg/dL (excluding Gilbert's syndrome), unless due to lymphoma~* ECOG performance status 0, 1 or 2.~Exclusion Criteria:~* Active concurrent malignancy with the exception of superficial non-melanoma skin cancer and cervical carcinoma in situ.~* Primary induction failure, defined as failure to achieve CR with first-line chemotherapy or chemoradiation, disease progression during first-line chemotherapy or chemoradiation, or progression or biopsy-proven disease persistence within 8 weeks of first-line therapy completion~* Prior brentuximab vedotin or rituximab for lymphoma~* Grade \> 2 peripheral neuropathy~* HIV infection, active hepatitis B infection, or active hepatitis C infection

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin & Rituximab (Type: EXPERIMENTAL): Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a \~ 1 year total course of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Impact of PET/CT on Radiation Treatment Planning in Relation to Changes in GTV in Stage 3 NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must be eligible for the Oncology FDG PET Winnipeg PET Program/Edmonton Cross Cancer Institute Extended Phase III Clinical Trial - Protocol 001, and in addition;~* Pathologically proven NSCLC~* Clinical stage III A (inoperable) or stage IIIB where there is intent to pursue radical curative RT/chemo, staged with conventional imaging as outlined in standard work up section.~* ECOG Performance status 0-2~* Age ≥ 18 years~* FEV1 ≥ 1.0 L~* No prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for one year or more for non primary bronchogenic cancers and two years for primary bronchogencic cancers;~* No prior RT to thorax.~* Must be able to start RT within 4 weeks after PET/CT simulation~* Participants may be treated with radical radiation only or without concurrent chemotherapy, adjuvant chemotherapy or neo-adjuvant therapy.~Exclusion Criteria:~* As per Oncology FDG PET Winnipeg PET Program/Edmonton Cross Cancer Institute Extended Phase III Clinical Trial - Protocol 001 and more specifically:~* Unable/unwilling to give informed consent.~* Uncontrolled hyperglycemia ( Blood sugar\> 12 mmol/L)~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Karnofsky index \> 60 % (ECOG \< 2)~* Histologically confirmed muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy.~* Pathological T-stage \> pT3, and/or pathological N-stage \> pN1, and/or residual tumor present after surgery (R\>1)~* No distant metastases~* Written informed consent~Exclusion Criteria:~* Prior RT in the pelvic region~* Presence of distant metastases~* Pregnancy~* Inability to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adiuvant Radiotherapy +/- CT (Type: EXPERIMENTAL): The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:~* R0: PTVb + PTVn 50 Gy in 25 fractions~* R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy~Patients with ECOG PS\<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 60~2. Mild depression~3. Inflammatory markers: CRP \> 2~Exclusion Criteria:~1. Non-English or Non-Spanish speakers~2. Active suicidal or homicidal ideation~3. Current alcohol or other substance abuse~4. Psychotic features~5. Current personality disorder~6. History of bipolar depressive disorder~7. Any current psychotic disorder~8. Current major depressive disorder~9. Current depression treatment or treatment within preceding 6 weeks~10. History of chronic liver and/or renal disease~11. Current use or contraindication to any of the tested medications~12. Absence of a response to a previous adequate trial of any of the tested medications~13. Pregnant or lactating women~14. History of coronary artery disease~15. Current use of statins~16. Current, regular aspirin use~17. Antibiotic use within the previous four weeks~18. History of diabetes~19. Inflammatory diseases~20. Meets NCEP guidelines for cholesterol lowering therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
- 2 (Type: PLACEBO_COMPARATOR): To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of HPS~* Age ≥ 18 years~Exclusion Criteria:~* Intracardiac shunting~* Pregnancy~* Known hypersensitivity to bosentan~* Use of glyburide~* Use of cyclosporin A~* Elevation of aminotransferase level of \> 3 times the upper limit of normal~* Use of rifampicin~* Females of childbearing potential without use of adequate contraception~* Systolic blood pressure \< 85 mmHg~* Clinical relevant anemia~* HIV-infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo tablets twice daily for 3 months.
- bosentan (Type: ACTIVE_COMPARATOR): pts. will receive bosentan for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bilateral Dual Transversus Abdominis Plane Block for Robotic Assisted Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for robotic assisted laparoscopis surgery~* acceptance to participate~Exclusion Criteria:~* allergies to local analgetics~* daily use of strong opioids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacain (Type: ACTIVE_COMPARATOR): Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
- Isotonic potassium chloride (Type: PLACEBO_COMPARATOR): Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pancreatic cancer patients ineligible for curative surgery at time of entry will be eligible for enrollment.~* Metastatic breast cancer at any time in their treatment history will be eligible for enrollment.~* Advanced stage (non-resectable/metastatic/incurable) lung cancer patients will be eligible for enrollment.~* Metastatic colon cancer patients not amenable to curative therapy will be eligible for enrollment.~* Metastatic non-resectable malignant melanoma patients will be eligible for enrollment.~NantHealth GPS Cancer in Advanced Cancers~* Metastatic hormone refractory prostate cancer patients will be eligible for enrollment. Patients must have tumor tissue available prior to the initiation of the current line of treatment available for GPS Cancer testing.~* Metastatic bladder cancer~* Non-resectable metastatic Renal carcinoma~* Non-resectable metastatic Head and Neck cancer~* Metastatic Ovarian cancer~* Metastatic Cervical cancer~* Metastatic Sarcoma~* Patients must sign informed consent for this study.~* Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs.~Exclusion Criteria:~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Concordant with GPS Cancer Test (Type: None): Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
- Discordant with GPS Cancer Test (Type: None): Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
- CNA controls without testing (Type: None): Retrospective patients in the COTA database matched by similar characteristics (CNA matched).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aneuploidies in Embryos and Spermatozoa From Patients With Y-chromosome Microdeletions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Couples with male infertility whose man has non-obstructive azoospermia or severe oligozoospermia with ≤5x1000000 spermatozoa/ml.~2. Assisted Reproductive Technology: ICSI with motile spermatozoa and PGS by CGH arrays.~3. Women \<38 years if microinjection is carried out in their own eggs, or 38≤ age \<50 years if they receive donated eggs.~4. Women with body mass index (BMI)\<30.~5. Men\<50 years~Exclusion Criteria:~1. Couples with abnormal karyotypes.~2. Women with any uterine pathology or abnormality, hydrosalpinx, thrombophilia or systemic diseases at the time of embryo transfer that could prejudge the outcome of the cycle~3. Couples with repeated miscarriages (≥2) or implantation failures (≥2).~4. Couples whose men has obstructive azoospermia, genital tract infections (mumps, inflammation, varicocele), cryptorchidism, or if he receives any treatment that can reduce the sperm count.~5. Seminal samples processed by Magnetic Activated Cell Sorting (MACS) technique.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Infertile with Y-chromosome deletions (Type: None): No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)
- Infertile without Y-chromosome deletions (Type: None): No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues